Immune checkpoint was another important target for glioma treatment and some immunotherapy drugs had entered clinical trials, inhibition of PD‐L1, CTLA4, Indoleamine 2,3‐dioxygenase (IDO) was included.67 The gene discussed is CTLA4; the disease is central nervous system cancer.